MPS Pharmaa Ltd.

BSE: 531686 SECTOR: Pharmaceuticals & Drugs  6179   13   0

2.20
0 0
BSE: 22 May 4:00 PM

Price Summary

Today's High

₹ 2.2

Today's Low

₹ 2.2

52 Week High

₹ 2.2

52 Week Low

₹ 0

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

4.2 Cr.

Enterprise Value

10 Cr.

No. of Shares

1.91 Cr.

P/E

0

P/B

1.36

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  1.62

CASH

0.01 Cr.

DEBT

5.81 Cr.

Promoter Holding

35.89 %

EPS (TTM)

₹  -0.16

Sales Growth

0%

ROE

-3.64 %

ROCE

-9.64%

Profit Growth

96.79 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year∞%
3 Year-66.06%
5 Year-59.14%

Profit Growth

1 Year96.79%
3 Year23.56%
5 Year14.65%

ROE%

1 Year-3.64%
3 Year-29.47%
5 Year-21.69%

ROCE %

1 Year-9.64%
3 Year-18.21%
5 Year-13.66%

Debt/Equity

1.5178

Price to Cash Flow

-0.97

Interest Cover Ratio

-241.16298758635

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2023 35.89 16.04
Dec 2022 35.89 16.04
Sep 2022 35.89 16.04
Jun 2022 35.89 16.04
Mar 2022 35.89 16.04
Investors List
* Figures given above are % of equity capital

 Strengths

 Looks like the company does not have any notable strengths.

 Limitations

  • The company has shown a poor revenue growth of -66.0603449380186% for the Past 3 years.
  • Company has a poor ROE of -29.472291614034% over the past 3 years.
  • Company has a poor ROCE of -18.2081566538142% over the past 3 years
  • Company has low Interest coverage ratio of -241.16298758635.
  • Company has high debtor days of 3546.46852509653.
  • Company has negative cash flow from operations of -4.3403637.
  • The company has a low EBITDA margin of -435.802158791792% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
Net Sales 0.03 0 0 0 0
Total Expenditure 0.2 0.19 0.17 0.24 0.23
Operating Profit -0.17 -0.19 -0.17 -0.24 -0.23
Other Income 0 0 0 0 0
Interest 0 0 0 0 0
Depreciation 0.13 0.13 0.04 0.04 0.04
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.29 -0.31 -0.21 -0.28 -0.26
Tax -0.02 -0.74 -0.01 -0.01 0
Profit After Tax -0.28 0.43 -0.2 -0.27 -0.26
Adjusted EPS (Rs) -0.14 0.22 -0.11 -0.14 -0.14

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 4.09 0.83 0 0 0.03
Total Expenditure 4.62 1.55 0.68 4.13 0.71
Operating Profit -0.53 -0.72 -0.67 -4.13 -0.67
Other Income 0.06 0.02 0.01 0.2 0.26
Interest 0 0 0 0 0
Depreciation 0.59 0.59 0.57 0.56 0.51
Exceptional Items 0 0 0 0 0
Profit Before Tax -1.06 -1.29 -1.24 -4.49 -0.93
Tax -0.19 -0.05 -0.07 -0.08 -0.79
Net Profit -0.87 -1.25 -1.17 -4.42 -0.14
Adjusted EPS (Rs.) -0.45 -0.65 -0.61 -2.31 -0.07

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 19.11 19.11 19.11 19.11 19.11
Total Reserves -8.35 -9.58 -10.75 -15.16 -15.29
Borrowings 0 0 0 0 0
Other N/C liabilities 0.88 0.8 0.74 0.69 0.25
Current liabilities 7.51 7.23 7.3 6.66 6.08
Total Liabilities 19.15 17.56 16.41 11.3 10.16
Assets
Net Block 6.47 5.88 5.26 4.68 4.17
Capital WIP 5.21 5.43 5.02 3.9 3.42
Intangible WIP 0 0 0 0 0
Investments 0.92 0.92 0.92 0.54 0.54
Loans & Advances 0 0 0.01 0.01 0.01
Other N/C Assets 0 0 0 0 0
Current Assets 6.55 5.32 5.2 2.19 2.02
Total Assets 19.15 17.56 16.41 11.3 10.16
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations -1.06 -1.29 -1.24 -4.49 -0.93
Adjustment 0.62 0.6 0.59 0.58 0.54
Changes in Assets & Liabilities 0.1 1.29 0.15 2.98 -3.95
Tax Paid 0 0 0 0 0
Operating Cash Flow -0.34 0.6 -0.49 -0.93 -4.34
Investing Cash Flow 0.3 -0.21 0.46 1.54 0.46
Financing Cash Flow 0 -0.39 0.03 -0.61 3.88
Net Cash Flow -0.04 0 0 0 0

Corporate Actions

Investors Details

PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Promoters 35.89 35.89 35.89 35.89 35.89
omkam pharmaceutic... 25.65 25.65 25.65 25.65 25.65
peeyush kumar agga... 10.24 10.24 10.24 10.24 10.24
PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Investors 64.11 64.11 64.11 64.11 64.11
vikas lifecare lim... 22.04 17.51 17.51 - -
pataliputra intern... - - - 17.51 17.51
dhiru builders and... - - - - -
dhiru builders and... 5.23 5.23 5.23 5.23 5.23
sangeetha s 6.71 6.71 6.23 6.23 6.23
sneha garg - 2.01 2.01 2.01 2.01
geeta garg - 1.99 1.99 1.99 1.99
sampark securities... 1.06 1.06 1.06 1.06 1.06

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

MPS informs about earnings presentation16 May 2023, 12:16PM MPS Pharmaa informs about compliance certificate18 Apr 2023, 1:09PM MPS Pharmaa - Quaterly Results3 Feb 2023, 2:54PM MPS Pharmaa - Quaterly Results3 Feb 2023, 2:54PM MPS Pharmaa - Quaterly Results3 Feb 2023, 2:54PM Advik Laboratories informs about board meeting16 Nov 2022, 5:22PM Advik Laboratories informs about newspaper publication14 Nov 2022, 5:07PM Advik Laboratories informs about disclosure10 Nov 2022, 12:33PM Advik Lab - Quaterly Results21 May 2022, 5:30PM Advik Lab - Quaterly Results21 May 2022, 5:30PM Advik Lab - Quaterly Results21 May 2022, 5:30PM Advik Laboratories planning to raise funds via various modes11 Apr 2022, 12:37PM Advik Laboratories informs about newspaper publication4 Mar 2022, 4:14PM Advik Laboratories submits EGM notice3 Mar 2022, 4:44PM Advik Laboratories informs about outcome of board meeting19 Feb 2022, 3:46PM Advik Laboratories informs about outcome of board meeting19 Feb 2022, 3:43PM Advik Lab - Quaterly Results10 Jan 2022, 3:07PM Advik Lab - Quaterly Results10 Jan 2022, 3:07PM Advik Lab - Quaterly Results10 Jan 2022, 3:07PM Advik Lab - Quaterly Results13 Oct 2021, 5:24PM Advik Lab - Quaterly Results13 Oct 2021, 5:24PM Advik Lab - Quaterly Results13 Oct 2021, 5:24PM Advik Laboratories informs about outcome of board meeting31 Aug 2021, 11:59AM Advik Laboratories informs about AGM notice8 Dec 2020, 3:41PM Advik Laboratories informs about book closure2 Dec 2020, 11:04AM Advik Laboratories informs about compliance certificate 27 Oct 2020, 10:49AM Advik Laboratories informs about disclosure 7 Apr 2020, 3:31PM

MPS Pharmaa Stock Price Analysis and Quick Research Report. Is MPS Pharmaa an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into MPS Pharmaa and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs -4.3403637 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. MPS Pharmaa has a Debt to Equity ratio of 1.5178 , which is a weak indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In MPS Pharmaa , the EPS growth was 96.7934570946384 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, MPS Pharmaa has OPM of -2079.4016988417 % which is a bad sign for profitability.
     
  • ROE: MPS Pharmaa have a poor ROE of -3.64091662143399 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about MPS Pharmaa

X